Drugs / Spirapril
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spirapril | “Spirapril 24mg/d” NCT02817360 ↗ |
| Known as | Espirapril | ChEMBL registry synonym — accepted as the source's own label CHEMBL431 ↗ |
| Known as | Renormax | ChEMBL registry synonym — accepted as the source's own label CHEMBL431 ↗ |
| Known as | SCH 33844 | ChEMBL registry synonym — accepted as the source's own label CHEMBL431 ↗ |
| Known as | Spirapril hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL431 ↗ |
| Known as | SPIRAPRIL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL431 ↗ |
| Action | Inhibit | “Angiotensin-converting enzyme inhibitor” CHEMBL431 ↗ |
| Modality | Small molecule | — CHEMBL431 ↗ |
| Target | ACE | “Angiotensin-converting enzyme inhibitor” CHEMBL431 ↗ |